Research Article
Serum Levels of Soluble ST2 and IL-10 Are Associated with Disease Severity in Patients with IgA Nephropathy
Table 2
Effect of treatment on the values of clinical measures in follow-up IgAN patients.
| | | Before treatment | After treatment |
| | Age, year | 46 (26–67) | 46 (26–67) | | Female/male | 4/5 | 4/5 | | Lymphocytes, 109/L | 2.14 (1.24–3.65) | 1.78 (1.11–3.21) | | Serum albumin, g/L | 29.7 (17.7–35.6) | 37.8 (25.8–48.2) | | Serum uric acid, μmol/L | 385 (263–583) | 352 (231–516) | | Triglycerides, mmol/L | 2.82 (1.24–5.46) | 2.55 (1.08–5.22) | | Cholesterol, mmol/L | 6.22 (3.28–9.26) | 5.17 (2.11–7.13) | | Urinary proteins, g/24 h | 4.41 (0.94–5.26) | 2.05 (0.38–3.32 | | Urea nitrogen, mmol/L | 5.71 (3.37–11.85) | 4.62 (2.65–9.38) | | eGFR, mL/min/1.73 m2 | 78.36 (48.74–102.85) | 99.73 (60.26–118.38 | | Microscopic hematuria, rbc/hpf | 6.65 (1.35–21.12) | 2.04 (0.21–10.23 | | Serum calcium, mmol/L | 1.81 (1.64–2.33) | 2.37 (2.09–2.58 | | Serum phosphorus, mmol/L | 1.78 (1.03–2.08) | 1.13 (0.81–1.45 | | Serum IgA, g/L | 3.27 (1.56–4.63) | 1.82 (1.12–3.76 |
|
|
Data are present as median (range). versus values before treatment.
|
